Last reviewed · How we verify
Pneumonia due to Streptococcus — Treatment Landscape & Competitive Intelligence
10 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Xenleta | LEFAMULIN | Hong Kong | Pleuromutilin Antibacterial | 2019-01-01 | ||
| Tygacil | TIGECYCLINE | Fresenius Kabi | Tetracycline-class Antibacterial [EPC] | 30S ribosomal subunit | 2005-01-01 | |
| Zymar | GATIFLOXACIN | Allergan | DNA gyrase, DNA gyrase, DNA gyrase subunit A | 2003-01-01 | ||
| Zyvox | linezolid | Pfizer | Oxazolidinone Antibacterial [EPC] | Amine oxidase [flavin-containing] A | 2000-01-01 | |
| Avelox | moxifloxacin | Bayer AG | Fluoroquinolone antibiotic (fourth-generation) | DNA gyrase, DNA gyrase subunit A, DNA topoisomerase 4 subunit A | 1999-12-10 | |
| Tomefloxacin | GREPAFLOXACIN | Otsuka | grepafloxacin | Potassium voltage-gated channel subfamily H member 2 | 1997-01-01 | |
| ALATROFLOXACIN | ALATROFLOXACIN | Pfizer | alatrofloxacin | 1997-01-01 | ||
| Levaquin | levofloxacin | Generic (originally Daiichi Sankyo/J&J) | Fluoroquinolone Antibacterial [EPC] | CAAX prenyl protease 2, Multidrug and toxin extrusion protein 1, Potassium voltage-gated channel subfamily H member 2 | 1996-12-20 | |
| Maxipime | CEFEPIME | Baxter | Cephalosporin Antibacterial | 1996-01-01 | ||
| Maxipime | Cefepime Hydrochloride | Baxter | Cephalosporin | Bacterial cell wall peptidoglycan | 1996-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- · 13 drugs in Pneumonia due to Streptococcus
- Pfizer · 6 drugs in Pneumonia due to Streptococcus
- GSK · 4 drugs in Pneumonia due to Streptococcus
- Bristol-Myers Squibb · 3 drugs in Pneumonia due to Streptococcus
- Bayer AG · 2 drugs in Pneumonia due to Streptococcus
- Baxter · 2 drugs in Pneumonia due to Streptococcus
- Pai Holdings Pharm · 2 drugs in Pneumonia due to Streptococcus
- Centre Hospitalier Universitaire Vaudois · 1 drug in Pneumonia due to Streptococcus
- Generic (originally Daiichi Sankyo/J&J) · 1 drug in Pneumonia due to Streptococcus
- Assistance Publique - Hôpitaux de Paris · 1 drug in Pneumonia due to Streptococcus
- Generic (originally Beecham/GSK) · 1 drug in Pneumonia due to Streptococcus
- Fresenius Kabi · 1 drug in Pneumonia due to Streptococcus
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Pneumonia due to Streptococcus:
- Pneumonia due to Streptococcus treatment updates — RSS
- Pneumonia due to Streptococcus treatment updates — Atom
- Pneumonia due to Streptococcus treatment updates — JSON
Cite this brief
Drug Landscape (2026). Pneumonia due to Streptococcus — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pneumonia-due-to-streptococcus. Accessed 2026-06-10.
Related
- Pneumonia due to Streptococcus full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing